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Brain barriers and functional 
interfaces with sequential 
appearance of ABC efflux 
transporters during human 
development
Kjeld Møllgård  1, Katarzyna M. Dziegielewska2, Camilla B. Holst  1, Mark D. Habgood2 & 
Norman R. Saunders  2
Adult brain is protected from entry of drugs and toxins by specific mechanisms such as ABC (ATP-
binding Cassette) efflux transporters. Little is known when these appear in human brain during 
development. Cellular distribution of three main ABC transporters (ABCC1, ABCG2, ABCB1) was 
determined at blood-brain barriers and interfaces in human embryos and fetuses in first half of 
gestation. Antibodies against claudin-5 and -11 and antibodies to α-fetoprotein were used to describe 
morphological and functional aspects of brain barriers. First exchange interfaces to be established, 
probably at 4–5 weeks post conception, are between brain and embryonic cerebrospinal fluid (eCSF) 
and between outer surface of brain anlage and primary meninx. They already exclude α-fetoprotein 
and are immunopositive for both claudins, ABCC1 and ABCG2. ABCB1 is detectable within a week of 
blood vessels first penetrating into brain parenchyma (6–7 weeks post conception). ABCC1, ABCB1 
and ABCG2 are present at blood-CSF barrier in all choroid plexuses from first appearance (7 weeks post 
conception). Outer CSF-brain interfaces are established between 9–11 weeks post conception exhibiting 
immunoreactivity for all three transporters. Results provide evidence for sequential establishment of 
brain exchange interfaces and spatial and temporal timetable for three main ABC transporters in early 
human brain.
An important feature of the developing brain is that it is separated from the general internal environment of the 
embryo and fetus by a complex series of interfaces composed of morphological structures, cellular transporters 
and various channels in cell membranes of each interface. Circumferential tight junctions sealing the intercellular 
space between cells of the interfaces create barriers with a diffusion restraint for lipid insoluble molecules. This 
diffusion restraint allows cellular transport mechanisms in the barrier to be established to provide the functional 
mechanisms that control the internal environment of the brain. These mechanisms are often referred to colloqui-
ally as “the blood-brain barrier”. However, this is a misleading simplification, since there are several distinct and 
unique interfaces protecting the brain. The two most well described barriers are the blood-brain barrier proper, 
with tight junctions between endothelial cells of brain vasculature and blood-CSF (cerebrospinal fluid) barrier 
with tight junctions between choroid plexus epithelial cells1. In addition to these two barriers there are another 
three main interfaces and a fourth that is present only in the embryonic brain (Supplementary Figure 1). The key 
structural component of all of these interfaces, except the CSF-brain interface, is the presence of tight junctions2. 
These barrier interfaces are described in more detail and illustrated in Supplementary Figure 1.
Compared to studies of the adult brain, the developing brain has been somewhat neglected until recent years. 
It is clear that many of the mechanisms present in the adult brain are not only present in the developing brain, 
but some may be functionally more active1, 3. There is also increasing evidence that some of the mechanisms may 
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be exclusive to the developing brain leading to the concept that the brain develops within a unique environment 
that is appropriate for different stages of its development1, 4. This is a far cry from the long-standing dogmatic 
evidence-free belief that “the” blood-brain barrier is leaky or absent in the embryo or even in the newborn (for 
discussion see ref. 5).
The two largest families of transporters in the barrier interfaces of the brain are the solute linked carriers 
(SLCs) and the ATP-binding cassette (ABC) transporters. In the mammalian brain the former are characteris-
tically influx transporters and the latter efflux transporters. The influx transporters have the important role of 
controlling the supply of nutrient molecules such as glucose, amino acids, monocarboxylates and key metal ions 
that are essential for the normal development and function of the brain1. The efflux transporters play a key role in 
the protective functional properties of the barrier6, 7 by removing metabolic products and preventing the entry of 
an astonishing number of potential toxins as well as most therapeutic drugs to which the brain may be exposed8. 
ABC efflux transporters are ubiquitously distributed throughout the organs and tissues of the body. Forty-nine 
members of the ABC protein superfamily have been described9. In the adult at the blood-brain barrier proper 
the efflux transporters that have been identified and appear to be of particular functional importance are: ABCB1 
(also known as P-glycoprotein or Multidrug Resistance Protein 1, MDR1) and ABCG2 (Breast Cancer Resistance 
Protein, BCRP) (cf. ref. 10). ABCC2 (Multidrug Resistance Protein 2, MRP2) and ABCC4 (MRP4) have also been 
demonstrated at this barrier7. At the blood-CSF barrier ABCC1 (Multidrug Resistance Protein 1, MRP1) appears 
to be the predominant efflux transporter, but ABCC4 (MRP4) and ABCG2 (BCRP) have also been shown to be 
present7, 11.
Of all the numerous cellular mechanisms that are present at various brain interfaces the least studied, par-
ticularly in the human embryo and fetus, are these efflux mechanisms. Efflux mechanisms are of considerable 
significance, not only because they are fundamental biological mechanisms important for normal function in 
the adult and developing brain but also because of their clinical relevance as potential protective mechanisms in 
the brain(see Discussion). In this study we report on the immunohistochemically defined spatial and temporal 
distribution of three key ABC transporters (ABCB1, ABCC1, ABCG2) in human embryonic and fetal brain. We 
describe their emergence and in some cases decline in the barrier interfaces of the developing human brain from 
the period of development before vascularization of the brain (i.e. before the advent of the blood-brain barrier 
itself), through the first appearance of the choroid plexuses, the first stages of CSF secretion and differentiation of 
the outer meningeal interfaces with subsequent establishment of the subarachnoid space.
Results
Adult brain is separated from the periphery by a set of morphological and physiological mechanisms that are 
present at various interfaces between the brain parenchyma and surrounding fluids. There are 5 main interfaces 
identified in the adult brain: (a) The arachnoid barrier, (b) The blood-brain barrier, (c) The blood-CSF barrier, (d) 
Circumventricular organs (CVO barrier), (e) The adult inner CSF-brain interface. An additional sixth interface, (f) 
The embryonic CSF-brain interface, is present only in the fetus. A brief summary is provided in the Supplementary 
Material (Supplementary Figure 1) in order to facilitate the understanding of results.
Here we present the data describing the sequential appearance of these barriers in the brain from the earliest 
embryonic stage (4–5 weeks post conception, wpc) to mid-gestation. The results are based on the individual barri-
ers and interfaces as they first become established. We used immunopositivity for the fetal protein, α-fetoprotein 
(AFP) to indicate the diffusional restraint to a large hydrophilic molecule (marker of passive permeability) and 
the distribution of ABC efflux transporters as a marker of potential functionality of individual interfaces.
The earliest brain interfaces (5 wpc): Primary meninx, eCSF-brain interfaces and blood-brain 
barrier proper. By 5 wpc the neural tube has closed around a fluid-filled neuronal cavity, initially filled with 
amniotic fluid but progressively modified and referred to as eCSF (embryonic cerebrospinal fluid)12 before the 
appearance of the choroid plexuses but also at a time when the brain tissue has barely begun to be vascularized. 
The first exchange interfaces that are present in and around the developing brain are: (i) between the brain and 
the trapped fluid (eCSF) resulting from neurotube closure that in humans occurs around 26 days post concep-
tion (dpc) and (ii) between the brain and vascular, neural crest-derived loose mesenchyme forming the primary 
meninx at the outer surface of the brain anlage13. At this stage of development the forebrain is still devoid of 
vasculature (Fig. 1).
One of the first fetal plasma proteins that is present in the human embryonic circulation is the fetal protein 
α-fetoprotein (AFP)14, 15. A sagittal section through 5 wpc human embryonic forebrain, stained with antibodies 
to AFP is shown in Fig. 1A. As can be seen a strong immunopositive signal is detected in the primary meninx on 
the outside of the forebrain anlage. There is also a fainter immunostaining on the surface of the inner eCSF-brain 
interface (Fig. 1A). Brain parenchyma is devoid of AFP staining indicating that embryonic forebrain, even at such 
an early stage of development, is already separated from entry of plasma proteins from the periphery. However, 
at the same stage of development (5 wpc) in the hind- and midbrains the first blood vessels have penetrated 
into the brain parenchyma. Antibodies to CD 34 demonstrate the presence of blood vessels (Fig. 1B) while anti-
bodies to claudin-5 demonstrate tight junctions present in these blood vessels (Fig. 1C). The tightness of these 
early penetrating blood vessels was further confirmed by staining consecutive sections with antibodies to AFP 
(Fig. 1D). This demonstrated that AFP was also kept out of the brain parenchyma in both mid- and hindbrains. 
This “tightness” of the blood-brain barrier, as demonstrated by claudin-5 positive endothelial cell tight junctions 
and exclusion of AFP from perivascular areas, persisted throughout the period investigated (Fig. 4A and ref. 16 
based on the same material).
ABC transporters. Antibodies to three main ABC transporters: ABCB1, ABCC1, ABCG2 were used to iden-
tify their distribution at these very early stages of human embryonic development. ABCB1 was not present in any 
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parts of the brain investigated, but was present in the placenta. Immunoreactivity for ABCB1 appears in blood 
vessels about one week later than for the other two transporters (see below), and all three transporters show con-
sistent positive signals on blood-brain barrier at least until 13 wpc.
Immunostaining for ABCG2 (Fig. 2A) shows positive signal in a dense perineural vascular plexus in the ven-
tral part of the upper spinal cord, the hindbrain (Fig. 3A2/B2) and the midbrain (Fig. 3A1/B1) whereas the dorsal 
forebrain is not yet vascularized as described above. Placenta is also very strongly stained for both transporters 
(Fig. 2A,B). Distribution of the immunostaining for ABCC1 (Figs 2B and 3B1,B2) is similar although it appears to 
be weaker than that for ABCG2. However tissue macrophages, present in primary meninx are especially strongly 
positive for ABCC1 (Fig. 2B). The eCSF-brain interface is also stained for ABCC1 (arrowheads in Fig. 2B). At this 
interface immunostaining for ABCG2 is less pronounced and not so uniform (Fig. 2A). At higher magnification, 
shown in Fig. 3, both transporters are clearly visible in all blood vessels in both the perineural vascular plexus 
and brain tissue.
The specificity of the antibodies was demonstrated in placental tissue (P) included in the sections (Fig. 2A,B). 
The syncytiotrophoblastic cell layer is strongly positive for both ABCG2 and ABCC1, and the prominent placen-
tal stromal macrophages (Hofbauer cells) are positive for ABCC1 (arrows in Fig. 2B). ABCC1 staining and lack of 
immunoreactivity for ABCG2 of both tissue macrophages and Hofbauer cells are clearly shown in Supplementary 
Figure 2, which additionally demonstrates Iba1 and CD58 immunoreactivity in these cell populations.
Blood-CSF barrier (7–10 wpc). Late in the 7th wpc the first choroid plexus epithelium differentiates in the 
4th ventricle. As soon as choroidal epithelium is visible, it is immunopositive for claudins-5 (Fig. 4A) and -11 
(Fig. 5A). In the next few days, lateral (Fig. 6) and finally 3rd ventricular choroid plexuses appear. The blood-brain 
and blood-CSF barriers develop together with markers of tight junctions (claudins-5 and -11) indicating that 
their permeability properties are likely to have been established. In a previous study of the distribution of AFP 
and other plasma proteins in developing human choroid plexus based on the same material more than 30% of 
early plexus epithelial cells showed a positive, clearly cellular AFP immunoreactivity from basolateral to apical 
membranes. There was no sign of paracellular reactivity and perivascular brain areas were negative for AFP17.
Figure 1. Markers for a large hydrophilic molecule (AFP), blood vessels (CD 34) and claudin-5 positive tight 
junctions (cld-5) in consecutive sagittal sections of a 5 wpc human embryonic brain anlage. Immunostaining 
for AFP (in A) in a sagittal section of 5 wpc human forebrain (FB) shows strong AFP signal in the loose 
mesenchyme surrounding the outer surface of the brain anlage and a weaker immunopositivity on the surface 
of the inner eCSF-brain interface (arrowheads). Note that the brain parenchyma in the forebrain is devoid of 
AFP immunostaining. In the midbrain and hindbrain (HB) blood vessels have already begun to penetrate the 
brain parenchyma as illustrated by CD 34 positive immunostaining (B), and display tight junctions as shown 
by claudin-5 positive immunostaining (C). The integrity of the early blood-brain barrier proper is further 
supported by lack of any perivascular AFP immunostaining in mid- and hindbrain (D). Note precipitated AFP 
(arrows) in the eCSF indicating its presence there. Abbreviations: eCSF: embryonic CSF; FB: forebrain; HB: 
hindbrain; OV: otic vesicle; SC: spinal cord, WPC: weeks post conception. (A–D) Same magnification. Scale bar: 
500 μm.
www.nature.com/scientificreports/
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ABC transporters. In the initial stages of choroid plexus epithelium differentiation, immunoreactivity 
of all three ABC efflux transporters is present on the luminal/apical surface and in the fenestrated vasculature 
(Fig. 4B,C,D). As the plexus grows into the lateral ventricle (Fig. 6), there is change in the cellular distribution 
of all three transporters. In the root of the plexus there is a strong reactivity in the apical surface, however in the 
more distal part the immunoreactivity becomes basolateral (Fig. 7). There are also regions of the plexus, which 
are devoid of any immunoreactivity for the transporters.
There are obvious differences in the pattern of distribution for ABCG2 (Fig. 7A), ABCC1 (Fig. 7B) and ABCB1 
(Fig. 7C) not only between the different efflux transporters per se but also within a given plexus stained for one of 
the transporters. The root of the plexus is positively stained in both cytoplasm and along apical and basolateral 
membranes for all three transporters but the leaflets of epithelial cells leading from either the ganglionic eminence 
or the hippocampal anlage show a different distribution of immunoreactivity. ABCG2 shows marked apical mem-
brane immunoreactivity extending from the surface of the ganglionic eminence along the ganglionic leaflet to the 
root of the plexus, whereas the leaflet connecting the root with the hippocampal anlage is unstained (Fig. 7A). 
ABCC1 immunoreactivity is present in both leaflets (Fig. 7B) while ABCB1 immunostaining is very strong in 
the apical membrane along the leaflet connecting the root with the hippocampal anlage in contrast to the leaflet 
towards the ganglionic eminence. However, closer to the ganglionic eminence the surface neuroepithelial layer 
becomes as positive as that covering the eminence (Fig. 7C). At higher magnification of a more peripheral part 
of the plexus (Fig. 7D) it is obvious that the ABCB1 immunoreactivity is most pronounced along the basolateral 
membranes also visualized in tangential sectioned epithelium as a honeycomb pattern (HCP). Endothelial cells 
of the fenestrated blood vessels are also positive.
Blood-CSF barrier (mid-gestation). ABC transporters. As the choroid plexus development progresses 
(up to mid-gestation) there is another distinct change in the distribution of the three transporters. ABCG2 immu-
noreactivity is strongly, but not uniformly present on the apical surface of the plexus (illustrated for 4th choroid 
Figure 2. Distribution of ABCG2 and ABCC1 immunoreactivity in consecutive sagittal sections of a 5 wpc 
human embryonic brain anlage. Immunostaining for ABCG2 (A) and ABCC1 (B) shows a dense perineural 
vascular plexus (PNVP) in the ventral part of the upper spinal cord (SC), the hindbrain (HB) and the midbrain 
(MB) but not in the dorsal forebrain, which lacks vascularization at this time. Note the many large tissue 
macrophages (MP) stained for ABCC1 in the loose vascular mesenchyme surrounding the brain anlage. The 
eCSF-brain interface is also immunopositive for ABCC1 (arrowheads in B). The boxed areas (A1, A2, B1, B2) 
are shown in higher magnification in Fig. 3. The specificity of the antibodies is demonstrated in placental tissue 
(P) included in the sections. The syncytiotrophoblastic cell layer is strongly immunopositive for ABCG2 and 
ABCC1, and the prominent placental stromal macrophages (Hofbauer cells) are immunopositive for ABCC1 
(arrows). Abbreviations: FB: forebrain; MB: midbrain; HB: hindbrain; MP: macrophages; OV: otic vesicle; P: 
placental tissue; PNVP: perineural vascular plexus; SC: spinal cord; TG: trigeminal ganglion; VCG: vestibulo-
cochlear ganglion, WPC: weeks post conception. (A,B) Same magnification. Scale bar: 1000 μm.
www.nature.com/scientificreports/
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plexus in Fig. 8). The strongest immunoreactivity is demonstrated in the fenestrated blood vessels (Fig. 8B). 
ABCG2 is also present in blood vessels in the neighboring cerebellum (Fig. 8A). In contrast to ABCG2, immu-
noreactivity for both ABCC1 and ABCB1 is absent in choroid plexus epithelial cells but ABCB1 is still present in 
some fenestrated blood vessels (Fig. 8C,D). Circumventricular organs, part of the exchange system between the 
brain and the CSF, are characterized by fenestrated blood vessels similar to those of the choroid plexus stroma. 
They follow the pattern of choroid plexuses, i.e. they are also immunopositive for all three transporters up to 13 
wpc, but at mid-gestation only ABCG2 shows strong reactivity as shown in the pineal gland (Fig. 8E).
Arachnoid barrier (7–10 wpc). At this stage of brain maturation there is a clear distinction in the pattern of 
development between blood-brain and blood-CSF barriers and the complex arachnoid barrier. This latter inter-
face develops over a prolonged period of weeks before there is a well-defined subarachnoid space, which includes 
the forebrain in contrast to blood-brain and blood-CSF barriers, which appear tight from their emergence in 
various brain regions and ventricles.
At 7 wpc the arachnoid barrier cell layer as shown by claudin-11 staining appears initially covering the inner 
surface of the tentorium cerebelli; it is most prominent in the medial part where the two ‘blades’ of the tentorium 
meet (insert in Fig. 5A). There is no indication of a claudin-11 positive arachnoid barrier cell layer covering the 
forebrain. At 10 wpc the basal forebrain shows a strongly claudin-11 positive arachnoid barrier cell layer, whereas 
the claudin-11 positive arachnoid membrane fades out along the dorso-medial surface (Fig. 5B) indicating that 
at this stage the infratentorial, fossa cranii posterior related part of the developing brain has a well-defined suba-
rachnoidal space in contrast to the forebrain. Only when the arachnoid formation is completed in 12th wpc is the 
entire subarachnoid space delineated and thus defined.
Arachnoid barrier (mid-gestation). By mid-gestation fully developed subarachnoid interfaces are established18. 
The subarachnoid space is delineated by the arachnoid barrier cell layer towards the dura and the end feet layer 
towards the brain dividing it into two individual interfaces: (i) the blood-arachnoid-outer CSF interface and (ii) 
the outer CSF-brain interface. In addition there is a third interface within the subarachnoid space between the 
outer CSF and the blood in the pial microvasculature (iii) the blood-pia microvessel-outer CSF interface. This 
vasculature in the subarachnoid space is characterized from the earliest development by claudin-5 positive tight 
junctions (Fig. 1B) that confer its barrier properties, confirmed by the exclusion of AFP.
Figure 3. Distribution of ABCG2 and ABCC1 immunoreactivity in a 5 wpc human embryonic brain anlage 
at high magnification. The boxed areas (A1, A2, B1, B2) from Fig. 2 are shown in higher magnification. Blood 
vessels showing ABCG2 and ABCC1 immunopositive endothelial cells from the perineural vascular plexus 
(PVNP) sprout to form radial branches that penetrate the marginal zone and then after reaching the ventricular 
zone (VZ) elongate as tangentially oriented longitudinal branches. Two such branches are seen in A2 (arrows). 
The eCSF-brain interface is outlined by ABCC1 immunoreactivity (arrowheads in B1 and B2). Abbreviations: 
HB: hindbrain; MB: midbrain; PNVP: perineural vascular plexus; TG: trigeminal ganglion; VZ: ventricular 
zone. WPC: weeks post conception. Scale bar: 100 μm in all panels.
www.nature.com/scientificreports/
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ABC transporters. Many ABCB1 and ABCG2 positively immunostained microvessels are visible within the 
subarachnoid space, SAS (Fig. 9A,B) but virtually no labeling of the vasculature for ABCC1 could be detected. 
ABCC1 is however present in numerous meningeal macrophages within the SAS at the end feet layer and the 
arachnoid barrier cell layer (Fig. 9C). Intensity of the immunostaining for ABCC1 appears to be declining after 
15 wpc in the microvessels but remains at similar levels in endothelium of larger arterioles and small arteries. In 
contrast immunoreactivity of both ABCG2 and ABCB1 remains constant but is never detected on endothelium 
of small arteries. Elongating radial vessels, which extend from the subarachnoidal space into the marginal zone, 
are positive for both ABCG2 and ABCB1 but not for ABCC1.
Inner CSF-brain interface (from 5 wpc – mid-gestation). The first fluid that is present in the brain ventricles is 
called eCSF12 and is derived from the amniotic fluid as it gets trapped following the closure of the neural tube. 
Secretion of the CSF begins following the appearance of the choroid plexuses19, 20. This now creates the inner 
CSF-brain interface. During development this interface changes its morphology and functional properties as has 
been described extensively for several species before13, 21–23. At early stages of sheep brain development, for exam-
ple, this interface is characterized by the presence of specific and specialized junctional complexes called strap 
junctions; these junctional complexes disappear as the brain matures and are replaced by gap junctions22. Strap 
junctions have also been identified in early fetal human brain24.
ABC transporters. The immunoreactivity for ABC transporters at the stage before choroid plexuses appear has 
been described earlier in this paper and illustrated in Figs 2 and 4. Once choroid plexuses are present within 
the brain ventricles, the inner CSF-brain interface is immunopositive for ABCG2 and ABCB1 at the ganglionic 
eminence but less so for ABCC1 (Fig. 6). The immunopositivity for ABCB1 covers the entire ganglionic emi-
nence down to the antihem from where the inner dorsolateral neocortical wall and the medial wall including the 
hippocampal anlage (HA) are devoid of signals. As described earlier in the result section, immunostaining of the 
inner CSF-brain interface shows marked regional differences clearly related to the area-specific differentiation of 
neuroepithelium to ependyma occurring over a broad range around mid-gestation. The outer CSF-brain inter-
face differentiates from an endfeet layer to a glia limitans after mid-gestation with concomitant changes in ABC 
transporters.
Figure 4. Claudin-5, ABCG2, ABCC1 and ABCB1 in the early developing 4th ventricular choroid plexus at 7 
wpc. Immunostaining of the emerging 4th ventricle choroid plexus at 7 wpc reveals claudin-5 in apical/luminal 
and basolateral membranes (A) and ABCG2 (B), ABCC1 (C), and ABCB1 (D) immunoreactivity in apical/
luminal membranes of choroidal epithelial cells facing the 4th ventricle (4 V) and in the fenestrated vasculature 
(arrows) (A–D). Note also the immunostaining of parenchymal blood vessels (arrowheads) illustrating the 
blood-brain barrier proper. Figures shown from 2 individual embryos. Abbreviations: CHP: choroid plexus; cld-
5: claudin-5; 4 V: fourth ventricle. WPC: weeks post conception. (A–D) Same magnification. Scale bar: 50 μm.
www.nature.com/scientificreports/
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Discussion
Limiting entry of potential neurotoxins to the brain is an essential function of brain barrier mechanisms, both 
during development and in the adult brain. This study of developing brain barriers and efflux mechanisms in 
human embryos and fetuses in the first half of gestation is the first in a series of two. Part two will describe second 
part of human gestation. Data presented so far provide evidence for two important aspects of early human brain 
development:
 (i) Distribution of immunostaining for the human fetal plasma protein AFP shows clearly that this protein, 
and presumably others in plasma, is excluded from the brain as soon as the neural tube closes and even 
before blood-brain barrier itself is present. This taken together with the finding that claudin-5 and/or -11 
are already present in every interface as each appears suggests that barriers in the human embryonic and 
fetal brain are “tight” as described in other animal species1, 5.
 (ii) The sequential appearance of three major ABC efflux transporters in the various brain barriers and 
interfaces as they appear in development suggests developmental adaptations at specific stages of brain 
maturation. In addition their cellular distribution also changes as the development progresses and their 
presence seems to be strongest at around 13 wpc, which is schematically indicated and described in Fig. 10 
and Table 1 as a general summary of the results so far. The potential clinical importance of these findings is 
discussed below.
In the early stages of vascularization of the brain a loose vascular ectomesenchyme rostral to the mesen-
cephalon derived from the neural crest continues caudally along the brain stem and spinal cord as a vascular 
mesenchyme originating from the paraxial mesoderm. This layer of loose mesenchymal tissue, which surrounds 
the neural tube and the developing early brain anlage has been termed the primary meninx (see refs 13, 18). Prior 
to the development of the dura and the leptomeninges (arachnoid, subarachnoid space and pia) an extensive 
microvascular network of interdigitating small arterioles, capillaries and venules termed the perineural vascular 
plexus (PNVP) is established by vasculogenesis at the surface of the neural tissue. Following differentiation of 
the leptomeninges from 7 to 10 wpc (see below) the PNVP will form the vasculature in the subarachnoid space.
Figure 5. Claudin-11 immunoreactivity in a 7 wpc embryo and a 10 wpc fetus. (A) 7 wpc embryo: the 
arachnoid barrier cell layer appears initially covering the inner surface of the tentorium cerebelli (TC); it is most 
prominent in the medial part where the ‘blades’ of the tentorium meet (insert). Note that there is no indication 
of a claudin-11 positive arachnoid layer covering the forebrain (A). The choroid plexus (CHP) of the 4th 
ventricle (4 V), positively immunostained for claudin-11, is starting to differentiate, and the sinuses are already 
present. (B) 10 wpc fetus: the basal forebrain shows a strongly claudin-11 immunopositive arachnoid barrier 
cell layer (four basolateral arrowheads) creating a well-defined subarachnoidal space in contrast to the dorso-
medial forebrain where the claudin-11 immunopositive arachnoid membrane fades out along the surface (three 
upper lateral arrowheads). Abbreviations: CHP: choroid plexus; 4 V: fourth ventricle; LV: lateral ventricle; OV: 
otic vesicle; PG: pineal gland; RL: rhombic lip; 3 V: third ventricle; SS: sigmoid sinus; ST: transverse sinus; TC: 
tentorium cerebelli; WPC: weeks post conception; cld: claudin. (A,B) Same magnification. Scale bar: 1000 μm.
www.nature.com/scientificreports/
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Figure 6. ABCC1, ABCG2 and ABCB1 immunoreactivity in coronal sections of a developing forebrain at 
8 wpc. Choroid plexus epithelial cells (CHP) and brain microvasculature show a positive immunoreactivity 
for ABCC1, ABCG2 and ABCB1 in adjacent sections from the same fetus at this early stage of development. 
In order to facilitate an overall comparison the left panel of the lower figure (ABCG2) is printed as a mirror 
image of that of the lower right panel (ABCB1) and the boxed areas (A,B,C) containing the choroid plexus are 
shown in higher magnification in Fig. 7. The arachnoid barrier cell layer in the ventral part of the forebrain is 
immunoreactive (arrowheads) in contrast to the dorsal surface and the developing superior sagittal sinus (SSS). 
Abbreviations: CHP: choroid plexus; GE: ganglionic eminence; H: hem; HA: hippocampal anlage; LV: lateral 
ventricle; SSS: superior sagittal sinus. WPC: weeks post conception. Scale bar: 1000 μm.
www.nature.com/scientificreports/
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Figure 7. Cellular distribution of ABCG2, ABCC1 and ABCB1 immunoreactivity in early lateral choroid 
plexus (8 wpc). Note obvious differences in the immunostaining for ABCG2 (A), ABCC1 (B) and ABCB1 
(C). The root of the plexus is positively stained in both cytoplasm and along apical and basolateral membranes 
in all efflux transporters but the leaflets of epithelial cells leading from either the ganglionic eminence or the 
hippocampal anlage (HA) show a different immunoreactivity. In the ABCG2 stained section (A) there is a 
marked apical membrane immunoreactivity extending from the surface of the ganglionic eminence along 
the ganglionic leaflet (arrowheads) to the root of the plexus whereas the leaflet connecting the root with 
the hippocampal anlage (HA) is unstained. In the ABCC1 stained section (B) both leaflets seem to be more 
equally reacting. In the ABCB1-immunostained section (C) there is very strong apical membrane reactivity 
(arrowheads) along the leaflet connecting the root with the hippocampal anlage (HA) in contrast to the leaflet 
towards the ganglionic eminence. However, closer to the ganglionic eminence the surface neuroepithelial layer 
becomes as immunopositive as that covering the eminence. In a higher magnification of a peripheral part of the 
www.nature.com/scientificreports/
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Vascularization of the human brain has been described in a number of studies25–27. Following the progressive 
proliferation of blood vessels over the surface of the brain, primordial vessels grow into the brain parenchyma 
from the primary meninx of the ventral surface of the developing brain. It has been suggested that this process 
begins in the 6th - 7th wpc28, 29. It is clear from the present study that the embryonic brain is protected from 
circulation-derived molecules such as AFP, even before the process of intrinsic angiogenesis begins. The first 
vessels penetrating into the brain parenchyma of the human embryo have characteristic brain barrier properties: 
they exclude AFP and are immunopositive for claudin-5.
Hemodynamics has been shown to have a major impact on arteriovenous specification and patterning28. 
Nevertheless evidence from animal studies indicates that endothelial cells in the developing brain are regulated 
by compartment-specific homeobox transcription factors and give rise to pial vessels and periventricular ves-
sels, which most likely form venous sinuses and arterial networks, respectively30, 31. Considering the differential 
expression of ABC transporters in brain vasculature in the present study, it is intriguing whether at least some of 
the ABC transporters relate to only the arterial or venous network.
There appear to be only very few reports describing ABC transporters in the human fetal brain with diverging 
results. Only the blood-brain barrier and blood-CSF barrier have been evaluated in detail. ABC efflux transport-
ers that appear to be of particular importance in brain barriers are ABCB1 and ABCG2 at the blood-brain barrier 
and ABCC1 at blood-CSF barrier10. ABCB1 is believed to act as a “flippase” transporting lipid-soluble substrates 
from the inner leaflet of the plasma membrane to the extracellular fluid32, as opposed to ABCC1 and ABCG2 that 
bind their substrates in the cell cytoplasm10. Considering the role of ABC transporters in neuroprotection and 
pharmacoresistance33 mapping their presence and spatiotemporal appearance in developing human brain will 
contribute to important knowledge of their functions and interactions.
ABCB1 is expressed in a variety of human tissues34, 35. A wide range of endogenous substrates and therapeutic 
drugs are substrates for this transporter34–36. In the developing human brain the presence of ABCB1 in brain 
capillaries at 28 weeks gestation but not earlier was reported37. Weak immunopositive staining for P-glycoprotein 
(ABCB1) in cerebral endothelial cells as early as 30 mm crown rump length (8 wpc), using the JSB-1 monoclonal 
antibody has been identified38. This was only present in the midbrain and brainstem regions. Later in gestation 
the endothelial immunostaining became progressively more pronounced and could be visualised in blood vessels 
of all major parts of the brain. The presence of P-glycoprotein has been confirmed in cerebral vascular endothe-
lial cells at 12, 18 and 22 weeks gestation (corresponding to 10, 16, and 20 wpc) using four different monoclonal 
antibodies including JSB-139. Immunocytochemically detectable P-glycoprotein, BCRP (ABCG2) and MRP-1 
(ABCC1) in mid- to late-gestation human fetuses (22–42 weeks gestation) compared to adult brain was also 
reported40. P-glycoprotein was only detected in brainstem and, “other regions of the hindbrain, and thalamus”, 
with no staining of forebrain vessels between 22 and 26 weeks gestation but an increase in immunostaining inten-
sity in older fetuses40. However, the material was from autopsies conducted 18–20 hours after death on live born 
neonates that died from a variety of pathologies, consequently much of the material is poorly fixed. Furthermore 
since several neurological diseases modulate the activity, location and expression of ABC transporters41, this may 
interfere with results. These considerations may account for some of the differences in immunostaining pattern 
between various studies38, 40. In contrast to the above findings a separate study reported that ABCB1 immunos-
taining was predominantly on the surface of neural stem/progenitor cells from 9 weeks gestation and was only 
detected in brain blood vessels in the adult42. In the present study ABCB1 immunostaining was found in placenta 
at 5 wpc, on brain endothelial cells about one week later and was strongest at the blood-brain barrier around 13 
wpc. Prior results of ABCB1 in choroid plexus suggest low levels, but subcellular and cellular localization remains 
unclear and data are mostly derived from animal studies7, 10. We found ABCB1 in fenestrated vasculature in cho-
roid plexus and a spatiotemporal gradient of immunostaining at the apical and basolateral surface of the choroid 
plexus epithelial cells, (which could explain some of the conflicting results in literature). At mid-gestation ABCB1 
was no longer present in choroid plexus epithelium, but immunoreactivity was still found in fenestrated vessels 
in choroid plexus and microvessels within the subarachnoid space. Our study therefore supports the presence 
of ABCB1 in the early blood-brain barrier, in vessels in the subarachnoid space and differential appearance in 
choroid plexus, although we did not see increasing staining after 13 wpc.
ABCC1 is considered to be a marker of the blood-CSF barrier33, 40, but evidence characterizing ABCC1 
in human development is sparse. ABCC1 was identified in choroid plexus epithelial cells, but not in cerebral 
endothelial cells at all ages from 22 weeks gestation and older40. ABCC1 was found in both the blood-CSF bar-
rier and blood-brain barrier in rats and human adult samples, although in a much lower level at the blood-brain 
barrier and with differences in reported activity7, 43. We found ABCC1 immunostaining in developing brain from 
5 wpc; initially in the perineural vascular plexus in the ventral part of the upper spinal cord, the hindbrain and 
the midbrain, parenchymal blood vessels, the whole eCSF-brain interface, placenta, Hofbauer cells and tissue 
macrophages in the primary meninx. As was the case for ABCB1 and ABCG2, ABCC1 was present in choroid 
plexus epithelial cells and fenestrated vasculature from the earliest development of choroid plexus, although the 
spatiotemporal distribution was different, and at mid-gestation ABCC1 was no longer present in the choroid 
plexus. ABCC1 immunoreactivity was seen in both the CSF-brain barrier, and at the level of the arachnoid barrier 
plexus (boxed area D) it is obvious that the ABCB1 immunoreactivity is most pronounced along the basolateral 
membranes (arrows in D) also visualized in tangential sectioned epithelium as a honeycomb pattern (HCP). 
Endothelial cells of the fenestrated blood vessels (BV) are also positive. Even at the low magnification in (A,B 
and C) it is possible to recognize positive blood vessels in the ganglionic eminences and in the subarachnoid 
space below the root of the choroid plexus. Abbreviations: BV: blood vessel; HA: hippocampal anlage; HCP: 
honeycomb pattern. (A–C) Same magnification. Scale bar: 200 μm. (D) Scale bar: 100 μm.
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Figure 8. ABCG2, ABCC1 and ABCB1 in the choroid plexus, cerebellum and the pineal gland at 19th wpc. 
Horizontal section through choroid plexus (CHP), cerebellum (CB) and pineal from a 19 wpc fetus. The microvessels 
on the surface of and within cerebellum (CB) are strongly immunopositive for ABCG2 (A) and can be easily 
identified even at this low magnification. In 4th ventricular choroid plexus (4 V) there is marked immunoreactivity of 
the fenestrated endothelial cells and of patches of the apical epithelial membranes. The boxed area is shown in higher 
magnification in (B). Endothelial cells of the fenestrated blood vessels (BV) depict a very strong immunoreactivity, 
which seems to fill the entire cytoplasm from luminal to abluminal membranes. Patches of subregions of the plexus 
show a distinct luminal/apical membrane (AM) immunoreactivity indicated by arrowheads but there is no sign of 
basolateral membrane staining. In (C) slender processes of stromal macrophages are immunopositive for ABCC1 
whereas there is no immunostaining of the fenestrated blood vessels (small arrows) and no immunoreactivity 
in the plexus epithelium. In (D) the vasculature of the plexus shows a differential immunostaining for ABCB1 
revealing some unstained blood vessels (small arrows) whereas others show a weak signal (arrowheads). There is 
no immunoreactivity in epithelial cells. Like choroid plexus, most circumventricular organs are characterized by 
fenestrated blood vessels. The pineal gland (PG) in (E) exhibits ABCG2 immunopositive endothelial cells like those 
of the 4th ventricular choroid plexus shown in (B). Abbreviations: AM: apical membrane; BV: blood vessel; CB: 
cerebellum; CHP: choroid plexus; 4 V: fourth ventricle, CHP: choroid plexus; PG: pineal gland, WPC: weeks post 
conception. Scale bars: (A) 500 μm, (B) 50 μm. (C,D) Same magnification. Scale bar: 100 μm; (E) Scale bar: 200 μm.
www.nature.com/scientificreports/
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cell layer and end feet layer in the arachnoid barrier. It also stained meningeal macrophages, but was sparse in the 
vasculature in SAS, in contrast to ABCB1 and ABCG2 immunoreactivity.
ABCG2 is thought to work synergistically with ABCB1 limiting transport through the blood-brain barrier33. 
In previous studies ABCG2 was identified in human fetal brain microvessels at all ages and brain regions exam-
ined from 22 weeks gestation and older, but not in choroid plexus40. Its immunostaining did not appear to vary 
with maturation. ABCG2 was shown to be associated with choroidal vessels but not choroidal epithelium during 
development in transgenic mice44. In the present studies, at 5 wpc we found ABCG2 immunoreactivity in peri-
neural vascular plexus and parenchymal blood vessels, placenta and eCSF-brain interface as for ABCC1, but with 
a less prominent and consistent staining in the eCSF-brain interface. In contrast to the two other transporters, 
the presence of ABCG2 was widespread in both choroid plexus epithelial cells and fenestrated vasculature of the 
plexuses at all ages examined and in microvessels in the subarachnoid space.
It is widely believed that the developing fetus and in particular its central nervous system is vulnerable to 
damage from maternally administered drugs45. Drugs used to treat neurological disorders (e.g. epilepsy or men-
tal illness) enter CNS because they are not substrates for protective efflux mechanisms at brain barriers or their 
functional capacity has been exceeded. In the developing brain it is possible that the functional capacity may be 
less than in the adult, thus allowing entry of a drug that would be excluded in the adult. Prescriptions for pregnant 
women and neonates are generally based on clinical experience and reports of adverse effects46. Notwithstanding 
placental protection, drugs have the potential to enter developing brain. The detailed description of when three 
of the main ABC efflux transporters appear in early brain development and particularly the finding that ABCG2 
is present from the earliest stage of central nervous system development, just after closure of the neural tube, 
Figure 9. ABCG2, ABCB1 and ABCC1 in the hippocampus at 19th wpc. Distribution of ABCG2, ABCB1 
and ABCC1 immunoreactivity in serial frontal sections through the hippocampus of a 19th wpc fetus. The 
subarachnoid space delineated by the arachnoid barrier cell layer (AR) towards the dura and the end feet layer 
(EFL) towards the brain still contains many ABCG2 and ABCB1 immunostained microvessels as shown in (A 
and B) but virtually no immunostaining of the vasculature for ABCC1, which seems to show immunoreactivity 
only of the numerous macrophages (MP), five of which are shown encircled, and of the arachnoid barrier cell 
layer (AR) and the end feet layer (EFL). Elongating radial vessels which extend from the subarachnoidal space 
into the marginal zone are immunopositive for both ABCG2 and ABCB1 as demonstrated in the two boxed 
areas in (A and B). Endothelium of the veins (V) shows no immunoreactivity. Abbreviations: AR: arachnoid 
barrier cell layer; EFL: end feet layer; MP: macrophage; V: vein, WPC: weeks post conception. (A–C) Same 
magnification. Scale bar: 200 μm.
www.nature.com/scientificreports/
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suggests that some degree of brain protection may already be present even in the embryo. This study provides 
an initial stage of the process aiming to understand efflux mechanisms operating in barriers in the developing 
human brain. This understanding is required in order to develop a rational basis for the safer prescription of 
drugs in pregnant women.
This study is a comprehensive investigation of ABC transporters in very early developing human brain. 
Assessing functional capacities of efflux transporters and efficacy of barrier mechanisms in the embryonic and 
fetal human brain is crucial for determining risk of fetal damage with maternal drug use45. The present results, 
demonstrating the morphological integrity of brain interfaces and presence of ABC transporters in these barriers 
even at the earliest stages in development, indicate that embryonic and early fetal brain may be better protected 
than expected with external (placenta) and internal (brain barriers) defense systems. Nevertheless spatiotemporal 
diversity in ABC transporter appearance, possible effects of genetic variability34 on ABC transporter function, 
modulation by other endogenous and exogenous compounds41 and interplay with other defense systems (such as 
placenta) paint a complex picture and complicate medical practice and risk assessment.
ABC transporter-mediated efflux protects the brain against toxic assaults, but unfortunately also prevents 
relevant therapeutic drugs from reaching the brain. ABC transporters are enhanced in several neurological disor-
ders41, which further limits drug penetration to the brain. Considering the broad substrate specificity and overlap 
of ABC transporters, inhibiting ABC transporters as a mean of increased penetration of specific drugs seems 
difficult10.
Figure 10. Schematic diagram of ABCG2, ABCC1 and ABCB1 distribution in an early human embryonic 
brain anlage and in a 13 wpc fetal brain. Diagram summarizes the data showing the spatial change in the 
distribution of ABCG2 (cyan), ABCC1 (yellow) and ABCB1 (magenta) in the early human embryonic brain 
anlage (A) and a 13 wpc fetal brain (B). (A): at 5 wpc ABCB1 (cyan) is not present in the brain anlage, ABCG2 
(magenta) immunoreaction is seen in parts of the ventral eCSF-brain interface, whereas ABCC1 (yellow) is 
detected over the whole of this interface as well as in macrophages located in the primary meninx. Both ABCG2 
and ABCC1 stain blood vessels of the perineural vascular plexus in the primary meninx as well as the first 
incoming brain parenchymal vessels. (B): at 13 wpc all three ABC transporters are at their maximum density 
of immunostaining compared to any other time during the first half of gestation. After this period there is 
a progressive decline in the intensity of ABCB1 and ABCC1 immunoreactivity. All three ABC transporters 
(cyan, magenta and yellow) are detected in brain parenchymal blood vessels, blood vessels in the subarachnoid 
space and subpopulations of choroid plexus epithelial cells at 13 wpc. In addition, ABCB1 and ABCG2 
immunostaining is present in fenestrated blood vessels of the choroid plexuses (cyan and magenta) and ABCC1 
(yellow) is present at several interfaces: the outer subarachnoid space, the outer surface of the brain and the 
inner CSF-brain interface; it is also present in macrophages in the choroid plexus stroma and subarachnoid 
space. See also Table 2. Abbreviations: ABC: arachnoid barrier cells; bm: basement membrane; BV: blood vessel; 
DBC: Dural border cells; EFL: end feet layer; f-BV: fenestrated blood vessel; i-CSF: inner cerebrospinal fluid; 
MP: macrophage; oCSF: outer cerebrospinal fluid; tj: tight junction.
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Further functional studies and a description of ABC transporters in second part of gestation are necessary to 
map the exact function and interaction of efflux transporters in the developing brain, which may help assessing 
risk of drug use for pregnant women and reveal new methods of increasing drug transport to the brain.
Materials and Methods
Tissue samples. Brains from ten human embryos (6–31 mm crown-rump length (CRL)) and 11 fetuses 
(38–200 mm CRL) corresponding to 5th-21st weeks post conception (wpc) were examined. The embryos and the 
fetuses were obtained from legal abortions, as previously described47. Informed consent was obtained from all 
contributing women following oral and written information, in accordance with the Helsinki declaration II, and 
approved by the Research Ethics Committee of the Capital Region (KF–V.100.1735/90). Full medical history of 
the women is also known. Post-operational treatment of tissue consisted of immediate dissection of the samples 
into blocks and subsequent fixation for 12–24 hours at 4 °C in either 10% neutral buffered formalin, 4% Formol-
Calcium, Lillie’s or Bouin’s fixatives. This procedure kept the time from delivery to fixation at a minimum, nor-
mally less than 2 hours, in order to retain optimal tissue quality. Most of the embryos were collected in relation 
to studies of smoking and alcohol in pregnancy and for schizophrenia in families. The numbers of embryos/
fetuses available for the study were: 5–6 wpc, 5; 7 wpc, 5; 8–11 wpc, 4; 12–15 wpc 6; 19–20 wpc, 2. For immuno-
histochemistry, 2–10 μm thick serial sections were cut in transverse, sagittal or horizontal planes, and placed on 
silanized glass slides.
Immunohistochemistry. Sections were deparaffinized and rehydrated in xylene following standard pro-
tocols. When necessary antigen retrival was performed (see Table 2) by 10 min boiling in citrate buffer, pH 6 or 
TEG pH 9. Endogenous peroxidase was quenched using a 0.5% solution of hydrogen peroxide in TBS for 15 min. 
Following rinses with TRIS buffered saline (TBS, 5 mM Tris-HCl, 146 mM NaCl, pH 7.6), non-specific binding 
Interfaces Present ABCB1 (PGP)
ABCG2 
(BCRP)
ABCC1 
(MRP1)
Age: 5 wpc Primary Meninx
blood vessels − ++ +
macrophages − − ++
Blood-brain barrier proper
blood vessels − ++ +
Inner eCSF-brain interface
neuroepithelium dorsal − − +
neuroepithelium ventral − + +
Arachnoid barrier
Age: 13 wpc arachnoid barrier cell layer − − ++
subarachnoid macrophages − − +++
pia microvessels +++ +++ ++
pial end feet layer − − ++
Blood-brain barrier proper
blood vessels +++ +++ ++
Blood-CSF barrier
blood vessels +++ +++ −
choroid plexus epithelium* +++ − +++ − +++ −
choroid plexus macrophages − − +++
Inner CSF-brain interface
neuroepithelium/ependyma − − ++
Table 1. Summary of results as illustrated in Fig. 10. *Staining present on a sub-population of epithelial cells. 
For details see legend to Fig. 10.
Primary antibodies Host IgG Dilution Retrieval Producer Code number
ABCB1/PGP Mouse IgG1 1:15–1:30 TEG Abcam ab3366
ABCC1/MRP1 Mouse IgG2a 1:30–1:50 M6 Abcam ab24102
ABCG2/BCRP Mouse IgG2a 1:15–1:20 M6 Abcam ab3380
AFP Rabbit IgGs 1:6000 — Dako A008
CD 34 Mouse IgG1 1:25 — Dako M7165
Claudin-5 Rabbit IgG 1:200 M6 Abcam ab15106
Claudin-11/OSP Rabbit IgG 1:800 — Abcam ab53041
Table 2. List of primary antibodies.
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was inhibited by incubation for 30 min with 10% normal goat serum at room temperature. The sections were 
incubated overnight at 4 °C with primary antibodies (Table 2) diluted in 10% normal goat serum and washed with 
TBS. For bright field light microscopy analysis, the REAL EnVision Detection System (Peroxidase/DAB + rabbit/
mouse, code K5007, DakoCytomation, Glostrup, Denmark) was used for detecting mouse and rabbit primary 
antibodies. The sections were washed with TBS, followed by incubation for 10 min with the DAB + solution. 
Positive staining was recognized as a brown color. The sections were counterstained with Mayers hematoxylin and 
dehydrated in graded alcohols and coverslipped with Pertex mounting medium.
Details of the primary antibodies including dilutions and suppliers are listed in Table 2. Control sections were 
incubated with mouse IgG1, IgG2a or irrelevant rabbit antibodies, as well as subjected to omission of primary or 
secondary antibodies. These were always blank. As positive controls we used placental tissue as the syncytiotroph-
oblastic cell layer is strongly immunopositive for ABCG2, ABCB1 and ABCC1, and the prominent placental 
stromal macrophages (Hofbauer cells) are positive for ABCC1.
Data Availability. The data that support the findings of this study are available from [Dr K Møllgård] but 
restrictions apply to the availability of these data, which were used under license for the current study, and so are 
not publicly available. Data are however available from the authors upon reasonable request and with permission 
of [Dr K Møllgård].
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